PLXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Protalix BioTherapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026

$2.56−0.06 (-2.29%)

Close on Oct 19, 2026

Market cap: $211.35M
P/E (TTM): 11.1
Dividend yield: –

Protalix BioTherapeutics, Inc. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31
Revenue	53	53	65	48	38	63	55	34	21	9.20	4.36	3.52	0	35	8.39	6.64	0.39
Cost of Revenue	27	24	23	20	16	11	11	9.30	15	8.40	0.73	0.63	0	8.14	1.53	4.38	3.58
Gross Profit	26	29	43	28	22	52	44	25	4.01	0.80	3.63	2.89	0	26	1.44	6.86	-3.19
Research & Development	20	13	17	29	30	38	45	33	32	30	25	27	29	37	38	38	27
Selling, General & Admin	12	12	15	12	13	11	9.90	11	12	9.36	7.28	9.23	8.05	9.76	–	–	–
General & Administrative	–	–	–	–	–	–	–	–	–	–	–	–	8.39	9.76	6.93	6.88	7.14
Operating Income	-5.50	3.92	10	-13	-20	2.71	-11	-19	-35	-33	-24	-29	-34	-12	-37	-30	-32
Interest Expense	–	–	–	–	–	–	–	–	–	–	3.55	3.55	1.02	–	–	–	–
Other Non-Operating Income	-0.11	0.24	-1.89	-1.38	-7.12	-9.23	-7.56	-7.15	-49	3.99	-3.61	-4.74	-0.67	0.55	0.00	–	–
Asset Impairment Charges	–	–	–	–	–	–	–	–	–	–	–	–	0	0	0.01	0.04	–
Gain (Loss) on Sale of Assets	0	0.00	-0.01	0	0.05	0	–	–	-0.01	0.01	0.00	0.00	–	–	-0.01	–	-0.03
Pretax Income	-5.61	4.15	8.57	-14	-28	-6.52	–	–	–	–	–	–	–	–	–	–	–
Income Tax Expense	1.00	1.22	0.25	0.53	–	–	–	–	–	–	–	–	–	–	–	–	–
Income from Continuing Operations	–	–	–	–	–	–	-18	-26	-83	-29	-27	-33	-35	–	–	–	–
Income from Discontinued Operations	–	–	–	–	–	–	–	–	–	-0.19	85	3.36	6.95	–	–	–	–
Net Income incl. Noncontrolling Interests	-6.60	2.93	8.31	-15	-28	-6.52	–	–	–	–	–	–	–	–	–	–	–
Net Income	-6.60	2.93	8.31	-15	-28	-6.52	-18	-26	-83	-29	58	-30	-28	-12	-37	-29	-31
Net Income to Common	-6.60	2.97	7.14	-15	-28	–	–	–	–	–	–	–	–	–	–	–	–
EPS (Basic)(per share)	-0.08	0.04	0.12	-0.31	-0.62	-0.22	-1.23	-1.80	-6.37	-2.90	6.10	-3.20	-3.00	-1.30	-4.30	-3.60	4.10
EPS (Diluted)(per share)	-0.08	0.04	0.09	-0.31	-0.62	-0.22	-1.23	-1.80	-6.37	-2.90	6.10	-3.20	-3.00	-1.30	-4.30	-3.60	4.10
Shares Outstanding (Basic, Weighted)(shares)	79	73	68	48	44	29	15	15	13	10	9.49	9.29	9.24	9.08	8.46	8.10	–
Shares Outstanding (Diluted, Weighted)(shares)	79	81	82	48	44	29	15	15	13	10	9.49	9.29	9.24	9.08	8.46	8.10	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 69.2%
Operating margin: 28.9%
Net margin: 23.5%
Return on equity, FY2025: -14.4%

Financial strength

Current ratio: 2.94
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 87.3%

Valuation

P/E ratio: 11.1
Price to sales: 2.62
Price to book: 2.96
Dividend yield: –